The $100 Billion Weight Loss Revolution That's Reshaping Your Portfolio

Related Articles

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

3 months ago

SanDisk Just Joined the S&P 500—Here's What That Actually Means for Your Portfolio

8 months ago

Is the AI Revolution Reshaping Mid-Cap Tech

4 months ago

From Value Meals to Weight-Loss Drugs: Navigating the Evolving Consumer Landscape

5 months ago

Category

You may also like

Stock News•1 week ago

Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?

Pfizer's weight-loss pipeline could capture a share of the $100B market, but it faces a steep challenge to overtake current leaders.

PFE

Share

Stock News•1 months ago

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Novo Nordisk's Wegovy pill filled over 3 million US prescriptions since its January 5 launch, marking one of the strongest pharma launches by volume, as GLP-1 drug markets expand into new disease indi...

GLP

Share

Stock News•1 months ago

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GLP

Share

Stock News•2 months ago

Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight

Novo Nordisk reported that a higher-dose Wegovy regimen enabled patients to lose 28% of their body weight. The clinical data indicates that 84% of this weight reduction originated from body fat, while...

NVO

Share